The European Patent Office will issue a formal grant for TheraCryf's drug, the 'Ox-1' receptor anatagonist, on December 18. The drug was developed by British biotech firm Chronos Therapeutics Ltd, ...

(Alliance News) - JPMorgan Global Core Real Assets Ltd on Wednesday said its loss narrowed in the first half of its current financial year, as the firm progresses its managed wind-down. The investment ...

The FTSE 100 index added 4.24 points, 0.1%, at 8,262.85. The FTSE 250 rose 15.49 points, 0.1%, at 20,584.14, and the AIM All-Share added 1.29 points, 0.2%, at 731.88. The Cboe UK 100 was flat at ...

In response, Iomart cut its interim dividend by 33% to 1.30 pence per share from 1.94p a year prior. In early October, Iomart announced an agreement to acquire Kookaburra Topco Ltd, the holding ...

Looking ahead, Gateley expects to deliver full-year results in line with market expectations, citing a company-compiled market consensus of GBP184 million in revenue, which would represent a 6.5% ...

(Alliance News) - Transense Technologies PLC on Wednesday said revenue and profit are up compared to last year and it expects to perform "at least in line" with market expectations. Oxfordshire, ...

Motorpoint attributed the increased profit to strong growth in retail volumes, and improved retail profit margins. Retail vehicles sold rose by 17% to 30,300 in the first half, from 25,800 a year ...

(Alliance News) - Focusrite PLC on Wednesday reported a sharp decline in annual pretax profit, citing soft demand and challenging market conditions. The High Wycombe, England-based software designer ...

Nationwide said that, since buying Virgin Money, it has booked an accounting gain of GBP2.3 billion, based on the value of the net assets acquired being above the price paid. Virgin Money also ...

The Finland-based developer of cancer immunotherapies said 20 patients with myelodysplastic syndrome, a rare blood cancer, had showed an 80% objective response rate in the ongoing BEXMAB trial.